|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.06 USD | +0.13% |
|
+0.52% | +9.38% |
| 05-16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
| 05-16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
Axonics, Inc. provided revenue guidance for the year 2023. For the year, the company expects to deliver net revenue of approximately $366 million, representing 34% growth over the prior fiscal year.
| 1st Jan change | Capi. | |
|---|---|---|
| +9.38% | 3.47B | |
| +14.55% | 127B | |
| +0.60% | 12B | |
| -20.95% | 6.88B | |
| +58.45% | 6.86B | |
| -15.63% | 2.54B | |
| -18.86% | 1.9B | |
| -28.80% | 1.58B | |
| -38.19% | 1.43B | |
| -14.52% | 1.08B |
AXONICS, INC. 
